35results about How to "Improved benefit/cost ratio" patented technology

The invention belongs to the field of medicine technology, provides a medicinal composition containing zafirlukast and statins, and also provides application of the medicinal composition in preparation of medicines for treating asthma disease. The medicinal composition provided by the invention specially contains two medicinal active components of zafirlukast and 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor, wherein the mass ratio of zafirlukast to the 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor is 1 to (0.01-10). In addition, a compound preparation provided by the invention can be prepared into an orally administered preparation or a parentarally administered preparation.

The invention discloses a medicine composition with active components of carvedilol and a medicinal salt thereof, and fimasartan. The invention also relates to an application of the medicine composition in treating hypertension and complications thereof, and an application of the medicine composition in treating congestive cardiac failure. In the medicine composition, a weight ratio of carvedilol and medicinal salt thereof to fimasartan is 1:0.01-1000. The components of the medicine composition are clear. When the medicine composition is used for treating hypertension and complications thereof, a substantial synergetic effect of the two medicine components is shown, and stable reduction of blood pressure can be realized; when the medicine composition is used for treating congestive cardiac failure, various cardiac indexes are substantially enhanced, a treatment effect is substantial, and a substantial synergetic effect of the two medicine components is shown.

The invention discloses a medicinal composition for treating hypertension, and belongs to the field of medicaments. The antihypertensive medicinal composition comprises a pharmaceutically effective dose of levoamlodipine or a pharmaceutically acceptable salt thereof and losartanpotassium, wherein the levoamlodipine is weighed in free alkali; the losartan is weighed in free acid; and the weight ratio of the levoamlodipine to the losartan is 1 to 11-19. The medicinal composition does not damage the target organ while reducing the blood pressure so as to enhance the therapeutic effect and reducethe risk for therapy of a patient.

The invention relates to a traditional Chinese medicine composition for treating male erectile dysfunction and an application thereof, belonging to the field of medicines. In order to overcome the defects that the existing medicine for treating male erectile dysfunction has the disadvantages of adverse reaction, short action time or slow effectiveness, the invention provides a traditional Chinese medicine composition capable of treating the male erectile dysfunction. The traditional Chinese medicine composition is mainly prepared from the following raw materials in parts by weight: 8-20 parts of cassia twig, 5-15 parts of glossy privet fruit, 5-15 parts of Rehmannia Glutinosa, 3-10 parts of herba epimedii, 10-25 parts of Chinese yam, 5-15 parts of morinda officinalis, 10-20 parts of Mangnolia officinalis, 3-10 parts of fresh ginger, 10-20 parts of prepared tuber of multiflower knotweed, 8-20 parts of astragalus, 5-12 parts of lily, 10-20 parts of poria cocos, 3-10 parts of cistanche, 5-15 parts of angelica sinensis, 3-10 parts of codonopsis pilosula, 3-10 parts of wolfberry, 5-12 parts of spina date seeds, 10-15 parts of scutellaria baicalensis, 10-20 parts of honeysuckle, 3-10 parts of fructus forsythiae, 5-15 parts of bighead atractylodes rhizome, 5-15 parts of the root of Chinese pulsatilla, 5-25 parts of Chinese gall and 10-20 parts of liquorice. The traditional Chinese medicine composition can obviously shorten the erection latency and obviously prolong the ejaculatory latency time and has an excellent effect of treating nervous ED.

The invention discloses a pharmaceutical composition containing cyanidenon and use thereof. The active component of the pharmaceutical composition is prepared from olmesartan medoxomil and cyanidenon, and the weight ratio of the olmesartan medoxomil to the cyanidenon is preferably 1:(2-20). The blood pressure can be slowly and stably reduced by adopting low-dosage cyanidenon combined with olmesartan medoxomil, so that protection of structure and function of the hypertensive target organ is facilitated, and the occurrence rate of a cardiovascular event is further reduced.